275 related articles for article (PubMed ID: 31980560)
21. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
22. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
23. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
24. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
28. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
29. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Sun WY; Lee YK; Koo JS
J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
[TBL] [Abstract][Full Text] [Related]
30. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy.
Neyaz A; Husain N; Kumari S; Gupta S; Shukla S; Arshad S; Anand N; Chaturvedi A
Histopathology; 2018 Oct; 73(4):622-633. PubMed ID: 29882997
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
[TBL] [Abstract][Full Text] [Related]
34. Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Tziakou P; Theodoropoulos G; Tsiambas E; Zizi-Sermpetzoglou A; Peschos D; Mastronikoli S; Thomopoulou G; Thymara E; Kavantzas N; Lazaris AC
Anticancer Res; 2021 Aug; 41(8):3809-3813. PubMed ID: 34281840
[TBL] [Abstract][Full Text] [Related]
35. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
36. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract][Full Text] [Related]
38. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
40. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
